Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 5Gastrointestinal 5Head & Neck 4Lymphoid 3CNS 3Thoracic 2Other solid neoplasm 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Gynecologic 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Valproic Acid × Thoracic × Clear all
NCT00634205 2015-02-12

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

European Lung Cancer Working Party

Phase 2 Completed
45 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT00759824 2015-02-12

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

European Lung Cancer Working Party

Phase 2 Completed
64 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡